Communiqués Marker Therapeutics, Inc.

Actions

MRKR

US57055L2060

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
1,050 ^USD	0,00%		-11,76%	-29,53%

22/09	Marker Therapeutics, Inc. met en avant l’élargissement des capacités de fabrication soutenant MT-601	CI
14/08	Marker Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

22/09	Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies	AQ
18/03	Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results	AQ
18/02	Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
26/01	Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology	AQ
06/01	Marker Therapeutics - Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer	AQ
05/01	Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer	AQ
14/11	Marker Therapeutics : Corporate Presentation	PU
14/11	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates	AQ
05/11	Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors	AQ
03/11	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting	AQ
06/10/25	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program	AQ
28/08/25	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
26/08/25	Marker Therapeutics : Corporate Presentation	PU
26/08/25	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma	AQ
30/07/25	Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference	AQ
17/06/25	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma	AQ
04/06/25	Marker Therapeutics : Corporate Presentation	PU
20/05/25	Marker Therapeutics : Lymphodepletion Enhances MAR-T Cell Response in Lymphoma	PU
20/05/25	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	AQ
19/05/25	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies	AQ
01/04/25	Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference	AQ
31/03/25	Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results	AQ
25/02/25	Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference	AQ
19/12/24	Marker Therapeutics : Provides a Clinical Update on MT 601 in Patients with Lymphoma Form 8 K	PU
19/12/24	Marker Therapeutics Announces $16.1 Million Private Placement	AQ